Shots:
- AbbVie has signed a definitive agreement to acquire Gilgamesh Pharmaceuticals’ Bretisilocin for moderate-to-severe major depressive disorder (MDD), currently in clinical development
- As per the deal, AbbVie will acquire Gilgamesh’s bretisilocin program for ~$1.2B, including upfront and milestone payments. Gilgamesh will spin off Gilgamesh Pharma Inc. to retain its team and other programs, including blixeprodil and its collaboration with AbbVie. The deal is subject to customary closing conditions
- Bretisilocin (GM-2505) is a short-acting serotonin 5-HT2A agonist and releaser, psychedelic compound in P-II development for major depressive disorder
Ref: AbbVie | Image: Gilgamesh Pharmaceuticals| Press Release
Related News:- Terumo to Acquire OrganOx for ~$1.5B
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
